Evaluate the Efficacy and Safety of rhuMAb Beta7 in Patients With Moderate to Severe Ulcerative Colitis

ClinicalTrials.gov ID: NCT01336465

Public ClinicalTrials.gov record NCT01336465. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 5, 2026, 6:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase II Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of rhuMAb Beta7 in Patients With Moderate to Severe Ulcerative Colitis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This Phase II study is a randomized, double-blind, placebo-controlled multicenter study to evaluate the efficacy and safety of rhuMAb Beta7 in patients with moderate to severe ulcerative colitis.

Study identification

NCT ID: NCT01336465
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Genentech, Inc.; Industry
Enrollment: 124 participants

Conditions and interventions

Conditions

Ulcerative Colitis

Interventions

placebo Drug
rhuMAb Beta7 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 75 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 31, 2011
Primary completion: Aug 31, 2012
Completion: May 31, 2013
Last update posted: Aug 11, 2016

2011 – 2013

United States locations

U.S. sites: 8
U.S. states: 8
U.S. cities: 8

Facility	City	State	ZIP	Site status
Not listed	San Diego	California	92103	—
Not listed	Gainesville	Florida	32610	—
Not listed	Atlanta	Georgia	30308	—
Not listed	Chevy Chase	Maryland	20815	—
Not listed	Ann Arbor	Michigan	48109-0682	—
Not listed	Rochester	Minnesota	55905	—
Not listed	Great Neck	New York	11021	—
Not listed	Cincinnati	Ohio	45219	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 43 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01336465, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 11, 2016 · Synced Sep 5, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01336465 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →